Forian Inc. Website

Forian Inc.

NasdaqCM-FORA

Company Overview

Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides clients with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain; and STEMS, a seed-to-sale tracking module, to provide cannabis program management solution to cannabis regulatory agencies. In addition, the company offers security monitoring and web marketing services. The company is headquartered in Newtown, Pennsylvania.

  • Name

    Forian Inc.

  • CEO

    Max C. Wygod

  • Website

    forian.com

  • Sector

    Health Care Technology

  • Year Founded

    2020

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 11, 2025 - Dec 11, 2025

Forian Inc Faces Challenges Amid Mixed Market Sentiment

  • Insider share surrender by CFO Michael Vesey signals management confidence.
  • Ongoing skepticism regarding operational metrics weighs on stock performance.
  • Macroeconomic pressures contribute to negative investor sentiment in the health care sector.

Over the past month, Forian Inc (FORA) experienced a decline of 2.3%. This underperformance is notable when compared to the S&P 500, which returned 0.3%, resulting in a relative underperformance of 2.5%. The Health Care sector, represented by XLV, also outperformed FORA with a return difference of -5.5%. These figures highlight a challenging environment for FORA amidst relatively stable market conditions.

On November 13, bullish sentiment surrounded FORA following Chief Financial Officer Michael Vesey's filing of a Form 4 with the SEC that disclosed his surrender of shares totaling 17,777 units. After this transaction, his direct holdings were reported at 612,605 shares. Investors perceived this insider activity as a positive sign and it contributed to an uptick in stock price on that day.

Despite this momentary boost driven by insider transactions signaling confidence in management’s commitment to governance practices and future direction, other factors negatively impacted FORA's overall performance throughout the month. Market reactions reflected skepticism regarding operational metrics and growth prospects due to reports highlighting challenges within their business model and competitive landscape.

The bearish sentiment was further exacerbated by macroeconomic indicators suggesting potential headwinds for health care stocks broadly due to regulatory changes and shifts in investor focus toward more stable sectors amid economic uncertainty. These pressures likely influenced negative investor behavior over several trading sessions leading up to mid-November.

Overall trends indicate that while there were moments of optimism tied specifically to corporate governance actions like insider share transactions from executives such as Vesey, these did not sufficiently counterbalance ongoing concerns about operational viability or external economic pressures impacting stock performance negatively over time compared with both sector peers and broader indices like the S&P 500. Forian Inc underperformed the Health Care (XLV) sector by -5.5%.

NasdaqCM:FORA